MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)

Peer Review reports

Original Submission
21 Dec 2020	Submitted	Original manuscript
11 May 2021	Reviewed	Reviewer Report
1 Jun 2021	Reviewed	Reviewer Report
14 Jun 2021	Author responded	Author comments - Ho Wai Derrick Siu
Resubmission - Version 2
14 Jun 2021	Submitted	Manuscript version 2
8 Jul 2021	Reviewed	Reviewer Report
9 Jul 2021	Author responded	Author comments - Ho Wai Derrick Siu
Resubmission - Version 3
9 Jul 2021	Submitted	Manuscript version 3
Publishing
19 Jul 2021	Editorially accepted
18 Aug 2021	Article published	10.1186/s12885-021-08644-4

Back to article page